ArticleJAAD case reports2025

Twelve-year continuous therapy with vismodegib for advanced basal cell carcinoma: Tolerability and partial reversibility of adverse events.

Marianne Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.